NeoGenomics Reports 159% Revenue growth to $59.7 Million and 442% Adjusted EBITDA increase to $8.2 Million, Driven by Clarient acquisition and Strong Volume Gains

Go back to NeoGenomics Reports 159% Revenue growth to $59.7 Million and 442% Adjusted EBITDA increase to $8.2 Million, Driven by Clarient acquisition and Strong Volume Gains
NEOGENOMICS (NASDAQ: NEO) Delayed: 17.38 -0.08 (0.46%)
Previous Close $17.46    52 Week High $9.54 
Open $17.20    52 Week Low $5.49 
Day High $17.47    P/E 434.50 
Day Low $16.87    EPS $0.04 
Volume 997,014